MBRX
Moleculin Biotech, Inc.
$2.40
-4.38%
$13.4M
No data for this timeframe.
Vol
Market Cap$13.4M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders3 funds
Inst. Value$51.7K
Inst. Activity1 buys / 0 sells
SEC Reports12
Press Releases1
Recent Activity
Jun 5, 2026
SEC
Moleculin Biotech announced results from an independent market landscape assessment for its lead drug Annamycin in relap
8-K — Impact 5/10
Jun 5, 2026
other
Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
<p align="center"><i>Surveyed oncologists reported high likelihood to prescribe (6 of 7), citing dee
May 29, 2026
SEC
Moleculin Biotech presented a pooled analysis at ASCO 2026 showing no detectable cardiotoxicity for its lead drug Annamy
8-K — Impact 6/10
May 26, 2026
SEC
Moleculin Biotech furnished a corporate investor presentation via an 8-K (Item 7.01). No new financial data, guidance, o
8-K — Impact 3/10
Inst.
VANGUARD GROUP INC — NEW
15,544 shares ($51.5K)
Mar 19, 2026
Press
Moleculin Biotech reported financial results for 2025, showing a net loss of $33.6 million and reduced R&D spending. The
Impact 6/10
Price Targets
$21.00
+775.0% upside
Strong Buy
Current $2.40
Low $10.00
Median $22.00
High $31.00
3 analysts
$10.00
$31.00
Analyst Ratings
2Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 24, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Dec 11, 2025 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.65 ▼ -13.0% | $-1.65 — $-1.65 | 87% YoY | 1 |
| Next Q | $-1.07 ▲ +1.8% | $-1.07 — $-1.07 | -57% YoY | 1 |
| Current FY | $-121.25 | $-121.25 — $-121.25 | -154% YoY | 1 |
| Next FY | $-110.50 | $-110.50 — $-110.50 | 9% YoY | 1 |
Latest Reports
BULLISH
8-K
5/10
Moleculin Biotech announced results from an independent market landscape assessment for its lead drug Annamycin in relap
Jun 5, 2026
BULLISH
8-K
6/10
Moleculin Biotech presented a pooled analysis at ASCO 2026 showing no detectable cardiotoxicity for its lead drug Annamy
May 29, 2026
MIXED
Press
6/10
Moleculin Biotech reported financial results for 2025, showing a net loss of $33.6 million and reduced R&D spending. The
Mar 19, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $51.5K | NEW |
| MORGAN STANLEY | $119.00 | — |
| BANK OF AMERICA CORP | $119.00 | — |
3 institutional holders with $51.7K total value (15,616 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, BANK. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 15,544 | $51.5K | 99.5% | NEW |
| 2 | MORGAN STANLEY | 36 | $119.00 | 0.2% | — |
| 3 | BANK OF AMERICA CORP /DE/ | 36 | $119.00 | 0.2% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | NEW | — | 15,544 | — | $51.5K | 2025-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
12 SEC filing reports analyzed. Sentiment: 4 bullish, 3 bearish, 1 mixed, 4 neutral. Avg impact: 5.2/10.
BULLISH
8-K
5/10
Moleculin Biotech announced results from an independent market landscape assessment for its lead dru
Jun 5, 2026
BULLISH
8-K
6/10
Moleculin Biotech presented a pooled analysis at ASCO 2026 showing no detectable cardiotoxicity for
May 29, 2026
NEUTRAL
8-K
3/10
Moleculin Biotech furnished a corporate investor presentation via an 8-K (Item 7.01). No new financi
May 26, 2026
NEUTRAL
8-K
4/10
Moleculin announced that an abstract on pooled cardiac safety data for Annamycin has been accepted f
May 22, 2026
BEARISH
PRESS-RELEASE
6/10
Moleculin Biotech reported Q1 2026 net loss of $12.8M ($3.54/share) vs $5.9M loss a year ago, with z
May 15, 2026
MIXED
8-K
6/10
Moleculin reported Q1 2026 results with no revenue, a net loss of $(14.6M) or $(3.54) per share, and
May 15, 2026
BULLISH
8-K
6/10
Moleculin Biotech announced preliminary blinded data from its pivotal Phase 2B/3 MIRACLE trial for A
May 13, 2026
NEUTRAL
8-K
3/10
Moleculin Biotech announced publication of an abstract at the EHA 2026 Congress showing no clinicall
May 12, 2026
NEUTRAL
8-K
3/10
Moleculin Biotech announced the issuance of a Hong Kong patent (No. 40073244) covering its proprieta
May 8, 2026
BULLISH
8-K
6/10
Moleculin Biotech announced preclinical data showing its drug candidate Annamycin significantly inhi
Apr 23, 2026
BEARISH
EFFECT
7/10
Moleculin Biotech's S-3 shelf registration became effective on April 14, 2026, allowing selling stoc
Apr 15, 2026
BEARISH
S-3
7/10
Moleculin Biotech filed an S-3 shelf registration to register 6,367,956 shares of common stock for r
Mar 27, 2026
Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 2 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$21.00 mean target
+775.0% upside
Strong Buy (3.00)
$10.00 Low
$31.00 High
| Metric | Value |
|---|---|
| Current Price | $2.40 |
| Target Low | $10.00 |
| Target Mean | $21.00 |
| Target Median | $22.00 |
| Target High | $31.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.65 | $-1.65 | $-1.65 | 86.5% | -13.0% | — | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-1.07 | $-1.07 | $-1.07 | -57.4% | +1.8% | — | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-121.25 | $-121.25 | $-121.25 | -153.8% | +0.0% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-110.50 | $-110.50 | $-110.50 | 8.9% | +0.0% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.650 | |
| 7d ago | $-1.460 | -0.190 |
| 30d ago | $-1.460 | -0.190 |
| 60d ago | $-1.395 | -0.255 |
| 90d ago | $-3.040 | +1.390 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 24, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Dec 11, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 5, 2026
other
Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
<p align="center"><i>Surveyed oncologists reported high likelihood to prescribe (6 of 7), citing deep remissions, transplant-bridging potential, bioma
Jun 4, 2026
other
Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment
<p align="center"><i>- Access the segment </i><a href="https://www.globenewswire.com/Tracker?data=m3wvkghcJspr424sMTW5PyO_mO_W69Kzvf8P6gK7hkMRSxjgV8Zw
May 29, 2026
other
Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
<p align="center"><i>Independent Cleveland Clinic Cardiac Review Supports Potential Best-in-Class Safety Profile as MIRACLE Phase 2b/3 Trial Advances<
May 21, 2026
routine
Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
<p align="justify"><b>HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc.</b>, (Nasdaq: MBRX) (“Moleculin” or the “Company”), today an
May 15, 2026
earnings
Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial
<p align="center"><i>Early blinded results show 40% composite complete remission rate across difficult-to-treat AML patient population in MIRACLE Tria
May 12, 2026
other
Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits
<p align="center"><i>Pooled analysis of 90 subjects across 5 trials shows stable </i><i>mean </i><i>ejection fraction and no clinically significant le
May 11, 2026
earnings_calendar
MBRX Q1 2026 Earnings Scheduled — 2026-05-11
May 8, 2026
other
Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin
<p align="center"><i>Solid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data Release</i></p>
Apr 23, 2026
other
Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026
<p align="center"><i>Non-cardiotoxic anthracycline demonstrates activity where traditional chemotherapies have historically failed, supporting potenti
Apr 21, 2026
routine
Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting
<p align="justify"><b>HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc.</b>, (Nasdaq: MBRX) (“Moleculin” or the “Company”), today
Apr 7, 2026
other
Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile
<p align="center"><i>Access the Moleculin CEO Corner </i><a href="https://www.globenewswire.com/Tracker?data=GX_lWIn46Ks3KkvcDOG42A_sfPkERrDecvB84F0O1
Mar 23, 2026
other
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout
<p align="justify"><b>HOUSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc.</b>, (Nasdaq: MBRX) (“Moleculin” or the “Company”), today
Mar 19, 2026
earnings
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026
<p align="justify"><b>HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc.</b>, (Nasdaq: MBRX) (“Moleculin” or the “Company”), today
Mar 19, 2026
earnings_calendar
MBRX Q4 2025 Earnings After Market Close — 2026-03-19
Mar 17, 2026
other
Moleculin to Present at 38th Annual ROTH Conference
<p align="center"><i>– Management to participate in fireside chat presentation with Jonathan Aschoff, Senior Research Analyst at ROTH Capital Partners